VETERINARY ONCOLOGY MARKET ANALYSIS

Veterinary Oncology Market, By Animal Type (Companion Animal (Equine, Canine, and Feline) and Livestock Animal), By Therapy Type (Chemotherapy, Combination Therapy, Immunotherapy, and Targeted Therapy), By Mode of Administration (Oral and Intravenous), By Application (Canine Lymphoma, Osteosarcoma (OSA), Mast Cell Cancer, Melanoma, and Others), By Distribution Channel (Hospital Pharmacies, Government Agencies, and Retail Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : May 2024
Code : CMI2995
Pages :225
Formats :
Excel and PDF
Industry : Pharmaceutical

Key Developments

On April 23, 2024, VolitionRx Limited, a pharmaceutical company, announced that its Nu. Q Vet Cancer Test is available to veterinarians across the United States and Europe through Antech, a veterinary diagnostics company. The Antech version of the product operates on the Element i+ Analyzer, providing veterinary teams with a quick, accurate, and cost-effective cancer screening tool for older patients or breeds that are high-risk.
In October 2023, Merck Animal Health, a subsidiary company of Merck & Co., Inc., announced that its caninized monoclonal antibody gilvetmab (gil-VET-mab) is available to veterinary specialists practicing oncology across the U.S. to treat dogs with mast cell tumors and melanoma
In July 2023, The University of Queensland, announced that they had launched vaccine trial for dogs with bone cancer. These treatments aim to stimulate a dog’s immune system to fight the spread of cancerous cells to other tissues of the body
In July 2022, CureLab Veterinary, a newly formed animal-health sister company to the human-focused Curelab Oncology, launched with exclusive worldwide rights to apply CureLab Oncology patents for treating dogs, cats, and horses. The first target market for CureLab Veterinary’s licensed DNA therapeutic will be to treat breast cancer in dogs and cats.
In July 2021, Elanco, an animal health company, announced that it had received an approval from the U.S. Food and Drug Administration for Tanovea (rabacfosadine injection) for the treatment of lymphoma in dogs